Metropolitan Life Insurance Co. NY acquired a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the first quarter, Holdings Channel reports. The institutional investor acquired 10,896 shares of the biopharmaceutical company’s stock, valued at approximately $385,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Quantbot Technologies LP bought a new position in shares of Esperion Therapeutics during the first quarter worth about $158,000. C WorldWide Group Holding A S bought a new position in shares of Esperion Therapeutics during the first quarter worth about $162,000. Princeton Alpha Management LP bought a new position in shares of Esperion Therapeutics during the first quarter worth about $205,000. Bank of Montreal Can increased its position in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the last quarter. Finally, American International Group Inc. increased its position in shares of Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 584 shares during the last quarter. 85.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics, Inc. (ESPR) traded down 0.80% during midday trading on Friday, reaching $44.62. 198,078 shares of the company traded hands. The firm has a 50-day moving average of $47.40 and a 200-day moving average of $36.29. The stock’s market capitalization is $1.01 billion. Esperion Therapeutics, Inc. has a 1-year low of $9.40 and a 1-year high of $57.38.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.67) by $0.25. During the same quarter in the prior year, the business earned ($0.62) earnings per share. On average, analysts predict that Esperion Therapeutics, Inc. will post ($7.39) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Metropolitan Life Insurance Co. NY Invests $385,000 in Esperion Therapeutics, Inc. (ESPR)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/18/metropolitan-life-insurance-co-ny-invests-385000-in-esperion-therapeutics-inc-espr.html.

A number of brokerages have issued reports on ESPR. UBS AG reissued a “buy” rating and set a $57.00 price objective (up from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Zacks Investment Research downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Bank of America Corporation reissued a “neutral” rating and set a $60.00 price objective on shares of Esperion Therapeutics in a research report on Friday, August 11th. Deutsche Bank AG set a $64.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $70.00 price objective (up from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $42.51.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.